The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.

<h4>Background</h4>Tuberculous pericardial effusion is a pro-fibrotic condition that is complicated by constrictive pericarditis in 4% to 8% of cases. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a ubiquitous tetrapeptide with anti-fibrotic properties that is low in tuberculous per...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayanda Trevor Mnguni, Mark E Engel, Megan S Borkum, Bongani M Mayosi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0143338
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839627740940075008
author Ayanda Trevor Mnguni
Mark E Engel
Megan S Borkum
Bongani M Mayosi
author_facet Ayanda Trevor Mnguni
Mark E Engel
Megan S Borkum
Bongani M Mayosi
author_sort Ayanda Trevor Mnguni
collection DOAJ
description <h4>Background</h4>Tuberculous pericardial effusion is a pro-fibrotic condition that is complicated by constrictive pericarditis in 4% to 8% of cases. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a ubiquitous tetrapeptide with anti-fibrotic properties that is low in tuberculous pericardial effusion, thus providing a potential mechanism for the heightened fibrotic state. Angiotensin-converting enzyme inhibitors (ACE-I), which increase Ac-SDKP levels with anti-fibrotic effects in animal models, are candidate drugs for preventing constrictive pericarditis if they can be shown to have similar effects on Ac-SDKP and fibrosis in human tissues.<h4>Objective</h4>To systematically review the effects of ACE-Is on Ac-SDKP levels in human tissues.<h4>Methods</h4>We searched five electronic databases (1996 to 2014) and conference abstracts with no language restrictions. Two reviewers independently selected studies, extracted data and assessed methodological quality. The protocol was registered in PROSPERO.<h4>Results</h4>Four studies with a total of 206 participants met the inclusion criteria. Three studies (106 participants) assessed the change in plasma levels of Ac-SDKP following ACE-I administration in healthy humans. The administration of an ACE-I was associated with an increase in Ac-SDKP levels (mean difference (MD) 5.07 pmol/ml (95% confidence intervals (CI) 0.64 pmol/ml to 9.51 pmol/ml)). Two studies with 100 participants further assessed the change in Ac-SDKP level in humans with renal failure using ACE-I. The administration of an ACE-I was associated with a significant increase in Ac-SDKP levels (MD 8.94 pmol/ml; 95% CI 2.55 to 15.33; I2 = 44%).<h4>Conclusion</h4>ACE-I increased Ac-SDKP levels in human plasma. These findings provide the rationale for testing the impact of ACE-I on Ac-SDKP levels and fibrosis in tuberculous pericarditis.
format Article
id doaj-art-a9c57321f5a544ca9b64657e2ce9e8cf
institution Matheson Library
issn 1932-6203
language English
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-a9c57321f5a544ca9b64657e2ce9e8cf2025-07-16T05:31:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014333810.1371/journal.pone.0143338The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.Ayanda Trevor MnguniMark E EngelMegan S BorkumBongani M Mayosi<h4>Background</h4>Tuberculous pericardial effusion is a pro-fibrotic condition that is complicated by constrictive pericarditis in 4% to 8% of cases. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a ubiquitous tetrapeptide with anti-fibrotic properties that is low in tuberculous pericardial effusion, thus providing a potential mechanism for the heightened fibrotic state. Angiotensin-converting enzyme inhibitors (ACE-I), which increase Ac-SDKP levels with anti-fibrotic effects in animal models, are candidate drugs for preventing constrictive pericarditis if they can be shown to have similar effects on Ac-SDKP and fibrosis in human tissues.<h4>Objective</h4>To systematically review the effects of ACE-Is on Ac-SDKP levels in human tissues.<h4>Methods</h4>We searched five electronic databases (1996 to 2014) and conference abstracts with no language restrictions. Two reviewers independently selected studies, extracted data and assessed methodological quality. The protocol was registered in PROSPERO.<h4>Results</h4>Four studies with a total of 206 participants met the inclusion criteria. Three studies (106 participants) assessed the change in plasma levels of Ac-SDKP following ACE-I administration in healthy humans. The administration of an ACE-I was associated with an increase in Ac-SDKP levels (mean difference (MD) 5.07 pmol/ml (95% confidence intervals (CI) 0.64 pmol/ml to 9.51 pmol/ml)). Two studies with 100 participants further assessed the change in Ac-SDKP level in humans with renal failure using ACE-I. The administration of an ACE-I was associated with a significant increase in Ac-SDKP levels (MD 8.94 pmol/ml; 95% CI 2.55 to 15.33; I2 = 44%).<h4>Conclusion</h4>ACE-I increased Ac-SDKP levels in human plasma. These findings provide the rationale for testing the impact of ACE-I on Ac-SDKP levels and fibrosis in tuberculous pericarditis.https://doi.org/10.1371/journal.pone.0143338
spellingShingle Ayanda Trevor Mnguni
Mark E Engel
Megan S Borkum
Bongani M Mayosi
The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
PLoS ONE
title The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
title_full The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
title_fullStr The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
title_full_unstemmed The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
title_short The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
title_sort effects of angiotensin converting enzyme inhibitors ace i on human n acetyl seryl aspartyl lysyl proline ac sdkp levels a systematic review and meta analysis
url https://doi.org/10.1371/journal.pone.0143338
work_keys_str_mv AT ayandatrevormnguni theeffectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT markeengel theeffectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT megansborkum theeffectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT bonganimmayosi theeffectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT ayandatrevormnguni effectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT markeengel effectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT megansborkum effectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis
AT bonganimmayosi effectsofangiotensinconvertingenzymeinhibitorsaceionhumannacetylserylaspartyllysylprolineacsdkplevelsasystematicreviewandmetaanalysis